Greenwich LifeSciences (GLSI) 10-Q 14 Aug 24 2024 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2024	Aug. 02, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-39555
Entity Registrant Name	GREENWICH LIFESCIENCES, INC.
Entity Central Index Key	0001799788
Entity Tax Identification Number	20-5473709
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	3992 Bluebonnet Dr.
Entity Address, Address Line Two	Building 14
Entity Address, City or Town	Stafford
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	77477
City Area Code	(832)
Local Phone Number	819-3232
Title of 12(b) Security	Common Stock
Trading Symbol	GLSI
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		13,144,653

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Current assets
Cash	$ 7,224,875	$ 6,989,424
Acquired patents, net	3,585	5,391
Total assets	7,228,460	6,994,815
Current liabilities
Accounts payable & accrued interest	1,335,231	256,317
Unreimbursed expenses	17,797	38,089
Total current liabilities	1,353,028	294,406
Total liabilities	1,353,028	294,406
Stockholders’ equity
Common stock, $0.001 par value; 100,000,000 shares authorized; 13,067,687 and 12,848,165 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively	13,068	12,848
Additional paid-in capital	61,306,810	57,052,130
Accumulated deficit	(55,444,446)	(50,364,569)
Total stockholders’ equity	5,875,432	6,700,409
Total liabilities and stockholders’ equity	$ 7,228,460	$ 6,994,815

Condensed Balance Sheets (Una_2

Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	13,067,687	12,848,165
Common stock, shares outstanding	13,067,687	12,848,165

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Revenue
Operating expenses
Research and development	2,307,873	1,379,567	4,502,386	3,207,474
General and administrative	353,531	368,259	696,219	781,434
Total operating expenses	2,661,404	1,747,826	5,198,605	3,988,908
Loss from operations	(2,661,404)	(1,747,826)	(5,198,605)	(3,988,908)
Interest Income	54,722	119,453	118,728	235,633
Net loss	$ (2,606,682)	$ (1,628,373)	$ (5,079,877)	$ (3,753,275)
Per share information:
Net loss per common share, basic	$ (0.20)	$ (0.13)	$ (0.39)	$ (0.29)
Net loss per common share, diluted	$ (0.20)	$ (0.13)	$ (0.39)	$ (0.29)
Weighted average common shares outstanding, basic	12,906,867	12,848,165	12,882,896	12,848,165
Weighted average common shares outstanding, diluted	12,906,867	12,848,165	12,882,896	12,848,165

Condensed Statements of Stockho

Condensed Statements of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balances at Dec. 31, 2022	$ 12,848	$ 54,674,042	$ (41,472,766)	$ 13,214,124
Balances, shares at Dec. 31, 2022	12,848,165
Stock-based compensation		594,522		594,522
Net loss			(2,124,902)	$ (2,124,902)
Sale of common stock via ATM program, net of costs, shares				0
Balances at Mar. 31, 2023	$ 12,848	55,268,564	(43,597,668)	$ 11,683,744
Balances, shares at Mar. 31, 2023	12,848,165
Balances at Dec. 31, 2022	$ 12,848	54,674,042	(41,472,766)	13,214,124
Balances, shares at Dec. 31, 2022	12,848,165
Net loss				(3,753,275)
Balances at Jun. 30, 2023	$ 12,848	55,863,086	(45,226,041)	10,649,893
Balances, shares at Jun. 30, 2023	12,848,165
Balances at Mar. 31, 2023	$ 12,848	55,268,564	(43,597,668)	11,683,744
Balances, shares at Mar. 31, 2023	12,848,165
Stock-based compensation		594,522		594,522
Net loss			(1,628,373)	(1,628,373)
Balances at Jun. 30, 2023	$ 12,848	55,863,086	(45,226,041)	10,649,893
Balances, shares at Jun. 30, 2023	12,848,165
Balances at Dec. 31, 2023	$ 12,848	57,052,130	(50,364,569)	6,700,409
Balances, shares at Dec. 31, 2023	12,848,165
Stock-based compensation		594,522		594,522
Net loss			(2,473,195)	(2,473,195)
Sale of common stock via ATM program, net of costs	$ 28	299,088		299,116
Sale of common stock via ATM program, net of costs, shares	27,117
Balances at Mar. 31, 2024	$ 12,876	57,945,740	(52,837,764)	5,120,852
Balances, shares at Mar. 31, 2024	12,875,282
Balances at Dec. 31, 2023	$ 12,848	57,052,130	(50,364,569)	6,700,409
Balances, shares at Dec. 31, 2023	12,848,165
Net loss				(5,079,877)
Balances at Jun. 30, 2024	$ 13,068	61,306,810	(55,444,446)	5,875,432
Balances, shares at Jun. 30, 2024	13,067,687
Balances at Mar. 31, 2024	$ 12,876	57,945,740	(52,837,764)	5,120,852
Balances, shares at Mar. 31, 2024	12,875,282
Stock-based compensation		594,522		594,522
Net loss			(2,606,682)	(2,606,682)
Sale of common stock via ATM program, net of costs	$ 17	266,725		266,742
Sale of common stock via ATM program, net of costs, shares	17,580
Sale of common stock via Private Placement, net of costs	$ 175	2,499,823		2,499,998
Sale of common stock via Private Placement, net of costs, shares	174,825
Balances at Jun. 30, 2024	$ 13,068	$ 61,306,810	$ (55,444,446)	$ 5,875,432
Balances, shares at Jun. 30, 2024	13,067,687

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Operating activities:
Net loss	$ (5,079,877)	$ (3,753,275)
Adjustments required to reconcile net loss to net cash used in operating activities:
Amortization	1,806	1,806
Stock-based compensation	1,189,044	1,189,044
Changes in operating assets and liabilities:
Accounts Payable	1,078,914	79,618
Unreimbursed expenses (accrued)	(20,292)	(40,977)
Net cash used in operating activities	(2,830,405)	(2,523,784)
Financing activities:
Sale of common stock via ATM program, net of costs	565,858
Sale of common stock via Private Placement, net of costs	2,499,998
Net cash provided by (used in) financing activities	3,065,856
Net increase (decrease) in cash	235,451	(2,523,784)
Cash, beginning of period	6,989,424	13,468,026
Cash, end of period	$ 7,224,875	$ 10,944,242

Organization and Description of

Organization and Description of the Business	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of the Business	1. Organization and Description of the Business Greenwich LifeSciences, Inc. (the “Company”) was incorporated in the state of Delaware in 2006 under the name Norwell, Inc. In March 2018, Norwell, Inc. changed its name to Greenwich LifeSciences, Inc. In February 2023, Greenwich LifeSciences Europe Limited was incorporated as a wholly owned subsidiary in Ireland. The Company is developing a breast cancer immunotherapy focused on preventing the recurrence of breast cancer following surgery.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Significant Accounting Policies	2. Significant Accounting Policies Basis of Presentation The accompanying unaudited interim condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission and should be read in conjunction with the audited financial statements and notes thereto of the Company contained elsewhere herein. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the condensed financial statements that would substantially duplicate the disclosures contained in the audited financial statements of the Company for the years ended December 31, 2023 and 2022 as reported in the Company’s Form 10-K have been omitted. Leases In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02-Leases (Topic 842), which significantly amends the way companies are required to account for leases. Under the updated leasing guidance, some leases that did not have to be reported previously are now required to be presented as an asset and liability on the balance sheet. In addition, for certain leases, what was previously classified as an operating expense must now be allocated between amortization expense and interest expense. The Company elected to adopt this update using the modified retrospective transition method and prior periods have not been restated. The current monthly rent is approximately $ 2,819 the underlying lease expires in July of 2026 Basic and Diluted Loss per Share As of June 30, 2024 and 2023, the Company had common stock equivalents related to warrants outstanding to acquire 20,174 As of June 30, 2024 and 2023, the Company had common stock equivalents related to options outstanding to acquire 1,498,128 As of June 30, 2024 and 2023, the Company has no The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated: Schedule of Basic and Diluted Net Loss Per Common Share 2024 2023 Six Months Ended June 30, 2024 2023 Basic and diluted net loss per share calculation: Net loss, basic (5,079,877 ) (3,753,275 ) Change in fair value of warrants — — Net loss, diluted (5,079,877 ) (3,753,275 ) Weighted average common shares outstanding, basic and diluted 12,882,896 12,848,165 Net loss per common share, basic and diluted $ (0.39 ) $ (0.29 )

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2024
Related Party Transactions [Abstract]
Related Party Transactions	3. Related Party Transactions Unreimbursed expenses have been accrued and incurred by management, which total $ 17,797 38,089 The aforementioned month-to-month sub-lease is from a related party and the underlying lease (lessor’s lease) expires in July of 2026.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	4. Commitments and Contingencies Accounts payable total $ 1,114,386 35,472 License Obligation, Legal Expenses, and Manufacturing Agreements The Company entered into an exclusive license agreement with The Henry M. Jackson Foundation (“HJF”) in April 2009, as amended, pursuant to which it acquired exclusive marketing rights to GP2, the Company’s product candidate. In consideration for such licensed rights, the Company issued HJF 202,619 0.267 15 3,607 220,845 Legal Proceedings From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of business. Any of these claims could subject the Company to costly legal expenses and, while management generally believes that there will be adequate insurance to cover different liabilities at such time the Company becomes a public company and commences clinical trials, the Company’s future insurance carriers may deny coverage or policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company’s reputation and business. The Company is currently not a party to any legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, could have a material adverse effect on our results of operations or financial position.

Stockholders_ Equity

Stockholders’ Equity	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Stockholders’ Equity	5. Stockholders’ Equity As of June 30, 2024, 893,181 908,362 120 2,009,657 15,181 34,157 no On January 23, 2022, the Board of Directors authorized the Company’s management to implement a stock repurchase program for up to $ 10 519,828 7,536,216 no On March 12, 2024, the Board of Directors further extended the lock-up of the shares owned by the Company’s directors, officers, and existing pre-IPO investors to June 30, 2025 (approximately 57 months from date of the Company’s IPO). During this period, current officers, directors and certain shareholders will not be able to sell their shares of the Company’s common stock unless otherwise modified by the Board of Directors. Between January 1, 2024 and June 30, 2024, the Company sold shares of its common stock pursuant to its ATM agreement with Jefferies, in which it issued and sold a total of 44,697 14.07 628,732 565,858 totaled 62,874 Warrants At June 30, 2024, outstanding warrants to purchase shares of common stock accounted for as equity were as follows with an aggregate intrinsic value as of June 30, 2024 of $ 203,203 17.26 Schedule of Outstanding Warrants Shares Underlying Outstanding Warrants Exercise Price (1) Expiration Date (1) 20,174 $ 7.1875 September 24, 2025 20,174 (1) The warrants are exercisable at any time and from time to time, in whole or in part, during a period commencing March 24, 2021 and expiring September 24, 2025 7.1875 6.9718 Options On June 22, 2022, prior to the close of the Nasdaq market, 1,498,128 7.63 9,512,356 3.2 106 4,815,628 4,696,728 2,437,540 four year Private Placement On June 13, 2024, prior to the close of the Nasdaq market, the Company completed a private placement offering pursuant to which it issued and sold 174,825 14.30 2,499,998

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	6. Subsequent Events Between July 1, 2024 and August 2, 2024, the Company sold shares of its common stock pursuant to its ATM agreement with Jefferies, in which it issued and sold a total of 76,966 17.06 1,312,692 1,181,424 131,269

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited interim condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission and should be read in conjunction with the audited financial statements and notes thereto of the Company contained elsewhere herein. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the condensed financial statements that would substantially duplicate the disclosures contained in the audited financial statements of the Company for the years ended December 31, 2023 and 2022 as reported in the Company’s Form 10-K have been omitted.
Leases	Leases In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02-Leases (Topic 842), which significantly amends the way companies are required to account for leases. Under the updated leasing guidance, some leases that did not have to be reported previously are now required to be presented as an asset and liability on the balance sheet. In addition, for certain leases, what was previously classified as an operating expense must now be allocated between amortization expense and interest expense. The Company elected to adopt this update using the modified retrospective transition method and prior periods have not been restated. The current monthly rent is approximately $ 2,819 the underlying lease expires in July of 2026
Basic and Diluted Loss per Share	Basic and Diluted Loss per Share As of June 30, 2024 and 2023, the Company had common stock equivalents related to warrants outstanding to acquire 20,174 As of June 30, 2024 and 2023, the Company had common stock equivalents related to options outstanding to acquire 1,498,128 As of June 30, 2024 and 2023, the Company has no The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated: Schedule of Basic and Diluted Net Loss Per Common Share 2024 2023 Six Months Ended June 30, 2024 2023 Basic and diluted net loss per share calculation: Net loss, basic (5,079,877 ) (3,753,275 ) Change in fair value of warrants — — Net loss, diluted (5,079,877 ) (3,753,275 ) Weighted average common shares outstanding, basic and diluted 12,882,896 12,848,165 Net loss per common share, basic and diluted $ (0.39 ) $ (0.29 )

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Schedule of Basic and Diluted Net Loss Per Common Share	The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated: Schedule of Basic and Diluted Net Loss Per Common Share 2024 2023 Six Months Ended June 30, 2024 2023 Basic and diluted net loss per share calculation: Net loss, basic (5,079,877 ) (3,753,275 ) Change in fair value of warrants — — Net loss, diluted (5,079,877 ) (3,753,275 ) Weighted average common shares outstanding, basic and diluted 12,882,896 12,848,165 Net loss per common share, basic and diluted $ (0.39 ) $ (0.29 )

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Schedule of Outstanding Warrants	Schedule of Outstanding Warrants Shares Underlying Outstanding Warrants Exercise Price (1) Expiration Date (1) 20,174 $ 7.1875 September 24, 2025 20,174 (1) The warrants are exercisable at any time and from time to time, in whole or in part, during a period commencing March 24, 2021 and expiring September 24, 2025 7.1875 6.9718

Schedule of Basic and Diluted N

Schedule of Basic and Diluted Net Loss Per Common Share (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Basic and diluted net loss per share calculation:
Net loss, basic			$ (5,079,877)	$ (3,753,275)
Change in fair value of warrants
Net loss, diluted			$ (5,079,877)	$ (3,753,275)
Weighted average common shares outstanding, basic			12,882,896	12,848,165
Weighted average common shares outstanding, diluted	12,906,867	12,848,165	12,882,896	12,848,165
Net loss per common share, basic	$ (0.20)	$ (0.13)	$ (0.39)	$ (0.29)
Net loss per common share, diluted	$ (0.20)	$ (0.13)	$ (0.39)	$ (0.29)

Significant Accounting Polici_4

Significant Accounting Policies (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Monthly rent	$ 2,819
Lease expires	the underlying lease expires in July of 2026
Common stock equivalents to warrants outstanding	20,174
Convertible Preferred Stock [Member]
Common stock equivalents	0	0
Common Stock [Member]
Common stock equivalents to warrants outstanding	20,174	20,174
Common stock equivalents to options outstanding	1,498,128	1,498,128

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Related Party Transaction [Line Items]
Unreimbursed expenses	$ 17,797	$ 38,089
Management [Member]
Related Party Transaction [Line Items]
Unreimbursed expenses	$ 17,797	$ 38,089

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	1 Months Ended	6 Months Ended
	Apr. 30, 2009	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accounts payable		$ 1,114,386		$ 35,472
Amortized value		1,806	$ 1,806
Accrued interest		$ 220,845		$ 220,845
License Agreement [Member] | The Henry M. Jackson Foundation ("HJF") [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares issued price per share	$ 0.267
License Agreement [Member] | The Henry M. Jackson Foundation ("HJF") [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares issued during period common stock	202,619
Amortized period	15 years
Amortized value	$ 3,607

Schedule of Outstanding Warrant

Schedule of Outstanding Warrants (Details)	Jun. 30, 2024 $ / shares shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares Underlying Outstanding Warrants	20,174
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares Underlying Outstanding Warrants	20,174
Exercise Price | $ / shares	$ 7.1875	[1]
Expiration Date	Sep. 24, 2025	[1]
[1]The warrants are exercisable at any time and from time to time, in whole or in part, during a period commencing March 24, 2021 and expiring September 24, 2025 7.1875 6.9718

Schedule of Outstanding Warra_2

Schedule of Outstanding Warrants (Details) (Parenthetical) - Warrant [Member]	Jun. 30, 2024 $ / shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expiration date	Sep. 24, 2025	[1]
Exercise price per share	$ 7.1875	[1]
Warrants Exercised within Six Months [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price per share	$ 6.9718
[1]The warrants are exercisable at any time and from time to time, in whole or in part, during a period commencing March 24, 2021 and expiring September 24, 2025 7.1875 6.9718

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)					3 Months Ended			6 Months Ended
	Jun. 13, 2024	Jun. 12, 2024	Jun. 22, 2022	Jan. 23, 2022	Jun. 30, 2024	Mar. 31, 2024	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Jun. 28, 2024
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares granted			1,498,128					893,181
Number of additional granted shares issued								120
Aggregate vested shares value					$ 2,009,657			$ 2,009,657
Number of unvested shares					15,181			15,181
Unrecognized value of shares					$ 34,157			$ 34,157
Stock repurchase value					266,742	$ 299,116
Repurchase of common stock, shares							519,828
Repurchase common stock value							$ 7,536,216
Stock repurchased during period, shares							0
Net proceeds from sale of shares								565,858
Aggregate intrinsic value of outstanding warrants					$ 203,203			203,203
Closing share price										$ 17.26
Exercise price			$ 7.63
Stock granted								$ 9,512,356
Risk-free interest rate								3.20%
Voltality rate								106%
Compensation expense								$ 4,815,628	$ 2,437,540
Fair value								$ 4,696,728
Vesting term									4 years
At The Market Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued								44,697
Public offering price					$ 14.07			$ 14.07
Gross proceeds from sale of shares								$ 628,732
Net proceeds from sale of shares								565,858
Underwriting discount commission and offering expenses								$ 62,874
Private Placement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares issued during period common stock	174,825
Shares issued price per share	$ 14.30
Private Placement [Member] | Chief Executive Officer And Director [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net proceeds from sale of shares		$ 2,499,998
Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock repurchase value				$ 10,000,000
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares granted								908,362
Common stock vested shares								0	0
Stock repurchase value					$ 17	$ 28
Stock repurchased during period, shares					(17,580)	(27,117)

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	1 Months Ended	6 Months Ended
	Aug. 02, 2024	Jun. 30, 2024	Jun. 30, 2023
Subsequent Event [Line Items]
Net proceeds from sale of shares		$ 565,858
At The Market Offering [Member]
Subsequent Event [Line Items]
Number of shares issued		44,697
Offering price		$ 14.07
Gross proceeds from sale of shares		$ 628,732
Net proceeds from sale of shares		565,858
Underwriting discount commission and offering expenses		$ 62,874
Subsequent Event [Member] | At The Market Offering [Member]
Subsequent Event [Line Items]
Number of shares issued	76,966
Offering price	$ 17.06
Gross proceeds from sale of shares	$ 1,312,692
Net proceeds from sale of shares	1,181,424
Underwriting discount commission and offering expenses	$ 131,269